tldrdaily.news logo

Eli Lilly's Experimental Obesity Drug Achieves Over 11% Weight Loss in Early Trials

1 min read
Source: Reuters
Eli Lilly's Experimental Obesity Drug Achieves Over 11% Weight Loss in Early Trials
Photo: Reuters
TL;DR Summary

Eli Lilly's experimental obesity drug, eloralintide, showed promising results in early trials, with some patients losing over 11% of their body weight in 12 weeks, and the drug appears to be safe and effective, potentially serving as a successor or complement to existing obesity treatments like tirzepatide.

Topics:business#clinical-trial#eli-lilly#eloralintide#health#obesity-drug#weight-loss
Share this article
  1. Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial  Reuters
  2. Lilly’s Experimental Obesity Drug Shows Promise in Early Study  Bloomberg.com
  3. Eli Lilly’s obesity drug causes 11% weight loss (LLY:NYSE)  Seeking Alpha
  4. Biotech behind Eli Lilly obesity pill aims for new standard of care  Financial Times
  5. Eli Lilly (LLY) Obesity Drug Shows Promising Results in Early Trial  GuruFocus

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

2 min

vs 2 min read

Condensed

88%

379 → 47 words

Want the full story? Read the original article

Read on Reuters